Asperolide A, a marine-derived tetranorditerpenoid, induces G2/M arrest in human NCI-H460 lung carcinoma cells, is mediated by p53-p21 stabilization and modulated by Ras/Raf/MEK/ERK signaling pathway

Marine Drugs

Volumn 11, Issue 2, 2013, Pages 316-331

  Lv, Cuiting ^a   Sun, Wenxia ^a   Sun, Haofen ^b   Wei, Shanjian ^a   Chen, Ruohua ^c   Wang, Bingui ^b   Huang, Caiguo ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Asperolide A; G2 M arrest; P53 p21; Ras Raf MEK ERK signaling pathway

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ASPEROLIDE A; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; DITERPENOID; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P21; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REPRESSION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG CANCER; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; M PHASE CELL CYCLE CHECKPOINT; MOUSE; NONHUMAN; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

EID: 84875776625     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md11020316     Document Type: Article

References (44)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer. J. Clin. 2011, 6, 69-90.
2. Navada, S.; Lai, P.; Schwartz, A.G.; Kalemkerian, G.P. Temporal trends in small cell lung cancer: Analysis of the national Surveillance Epidemiology and End-Results (SEER) database. J. Clin. Oncol. 2007, 25, 5570-5577.
3. American Cancer Society Surveillance Research. Cancer Facts and Figures 2004; American Cancer Society: Atlanta, GA, USA, 2004; pp. 1-60.
4. Molina, J.R.; Yang, P.; Cassivi, S.D. Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83, 584-594.
5. Shen, L.; Li, Z.; Shen, S.; Niu, X.; Yu, Y.; Li, Z.; Liao, M.; Chen, Z.; Lu, S. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Lung Cancer 2012, 78, 193-200.
6. Omenn, G.S.; Goodman, G.E.; Thornquist, M.D.; Balmes, J.; Cullen, M.R.; Glass, A.; Keogh, J.P.; Meyskens, F.L., Jr.; Valanis, B.; Williams, J.H., Jr.; et al. Risk factors for lung cancer and for intervention effects in CARET, the β-Carotene and Retinol Efficacy Trial. J. Natl. Cancer Inst. 1996, 88, 1550-1559.
7. Das, A.; Bortner, J.; Desai, D.; Amin, S.; El-Bayoumy, K. The selenium analog of the chemopreventive compound S,S′-(1,4-phenylenebis[1,2- ethanediyl]) bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer. Chem. Biol. Interact. 2009, 180, 158-164.
8. Reungwetwattana, T.; Weroha, S.J.; Molina, J.R. Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin. Lung Cancer 2012, 13, 252-266.
9. Salomon, D.S.; Brandt, R.; Ciardiello, F. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
10. Woessmann, W.; Chen, X.; Borkhardt, A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol. 2002, 50, 397-404.
11. Bacus, S.S.; Gudkov, A.V.; Lowe, M.; Lyass, L.; Yung, Y.; Komarov, A.P. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 2001, 20, 147-155.
12. Tang, D.; Wu, D.; Hirao, A.; Lahti, J.M.; Liu, L.; Mazza, B. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 2002, 277, 12710-12717.
13. Luk, P.P.; Galettis, P.; Links, M. ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478. Lung Cancer 2011, 73, 274-282.
14. Smalley, K.S. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int. J. Cancer. 2003, 104, 527-532.
15. Sun, H.F.; Li, X.M.; Meng, L.; Cui, C.M.; Gao, S.S.; Li, C.S; Huang, C.G.; Wang, B.G. Asperolides A-C, tetranorlabdane diterpenoids from the marine alga-derived endophytic fungus Aspergillus wentii EN-48. J. Nat. Prod. 2012, 75, 148-152.
16. Zhang, W.; Liu, H.T. MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002, 12, 9-18.
17. Han, Y.H.; Kim, S.Z.; Kim, S.H.; Park, W.H. Arsenic trioxide inhibits the growth of Calu-6 cells via inducing a G2 arrest of the cell cycle and apoptosis accompanied with the depletion of GSH. Cancer Lett. 2008, 270, 40-55.
18. Porter, L.A.; Donoghue, D.J. Cyclin B1 and CDK1: Nuclear localization and upstream regulators. Prog. Cell Cycle Res. 2003, 5, 335-347.
19. Roshak, A.K.; Capper, E.A.; Imburgia, C.; Fornwald, J.; Scott, G.; Marshall, L.A. The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase. Cell Signal. 2000, 12, 405-411.
20. Meek, D.W. The role of p53 in the response to mitotic spindle damage. Pathol. Biol. 2000, 48, 246-254.
21. Yin, X.Y.; Grove, L.; Datta, N.S.; Long, M.W.; Prochownik, E.V. c-myc overexpression and p53 loss cooperate to promote genomic instability. Oncogene 1999, 18, 1177-1184.
22. Bates, S.; Vousden, K.H. Mechanisms of p53-mediated apoptosis. Cell. Mol. Life Sci. 1999, 55, 28-37.
23. Vogt Sionov, R.; Haupt, Y. The cellular response to p53: The decision between life and death. Oncogene 1999, 18, 6145-6157.
24. Vousden, K.H. p53: Death star. Cell 2000, 103, 691-694.
25. Chen, X.; Ko, L.J.; Jayaraman, L.; Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response o tumor cells. Genes Dev. 1996, 10, 2438-2451.
26. Duliæ, V.; Stein, G.H.; Far, D.F.; Reed, S.I. Nuclear accumulation of p21Cip1 at the onset of mitosis: A role at the G2/M-phase transition. Mol. Cell. Biol. 1998, 18, 546-557.
27. Niculescu, A.B., III; Chen, X.; Smeets, M.; Hengst, L.; Prives, C.; Reed, S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell. Biol. 1998, 18, 629-643.
28. Vogelstein, B.; Lane, D.; Levine, A.J. Surfing the p53 network. Nature 2000, 408, 307-310.
29. Vousden, K.H.; Lane, D.P. p53 in health and disease. Nat. Rev. Mol. Cell. Biol. 2007, 8, 275-283.
30. Darbinyan, A.; Darbinian, N.; Safak, M.; Radhakrishnan, S.; Giordano, A.; Khalili, K. Evidence for dysregulation of cell cycle by human polyomavirus, JCV, late auxiliary protein. Oncogene 2002, 21, 5574-5581.
31. Taylor, W.R.; Stark, G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20, 1803-1815.
32. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J.P.; Sedivy, J.M.; Kinzler, K.W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282, 1497-1501.
33. Drukteinis, J.S.; Medrano, T.; Ablordeppey, E.A.; Kitzman, J.M.; Shiverick, K.T. Benzo[a]pyrene, but not 2,3,7,8-TCDD, induces G2/M cell cycle arrest, p21CIP1 and p53 phosphorylation in human choriocarcinoma JEG-3 cells: A distinct signaling pathway. Placenta 2005, 26, S87-S95.
34. Moodie, S.A.; Willumsen, B.M.; Weber, M.J.; Wolfman, A. Complexes of Ras-GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993, 260, 1658-1661.
35. Khosravi-Far, R.; Solski, P.A.; Clark, G.J.; Kinch, M.S.; Der, C.J. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol. Cell. Biol. 1995, 15, 6443-6453.
36. Waskiewicz, A.J.; Cooper, J.A. Mitogen and stress response pathways: MAP kinase cascades and phosphatase regulation in mammals and yeast. Curr. Opin. Cell Biol. 1995, 7, 798-805.
37. Campbell, S.L.; Khosravi-Far, R.; Rossman, K.L.; Clark, G.J.; Der, C.J. Increasing complexity of Ras signaling. Oncogene 1998, 17, 1395-1413.
38. Xia, Z.; Dickens, M.; Raingeaud, J.; Davis, R.J.; Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270, 1326-1331.
39. Rush, V.; Klimstra, D.; Venkatraman, E.; Oliver, J.; Martini, N.; Gralla, R.; Kris, M.; Dmitrovsky, E. Aberrant p53 expression predicts clinical resistance to cisplatinum-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 1995, 55, 5038-5042.
40. Fujiwara, T.; Grimm, E.A.; Mukhopadhyay, T.; Zhang, W.-W.; Owen-Schaub, L.B.; Roth, J.A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994, 54, 2287-2291.
41. Fan, S.; El-Deiry, W.S.; Bae, I.; Freeman, J.; Jondle, D.; Bhatia, K.; Fornace, A.J., Jr.; Magrath, I.; Kohn, K.W.; O'Connor, P.M. The p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA-damaging agents. Cancer Res. 1994, 54, 5824-5830.
42. Giaccone, G. Clinical perspectives on platinum resistance. Drugs 2000, 59, 37-38.
43. Stordal, B.; Davey, M. Understanding cisplatin resistance using cellular models. IUBMB Life 2007, 59, 696-699.
44. Zhang, C.; Wang, W.; Liu, T.; Wu, Y.; Guo, H.; Wang, P. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemo-therapy. Biomaterials 2012, 33, 2187-2196.